Boston Scientific Corp $ 42.62 0.12 (0.28%)
On watch
Volume:
7,282,359
Avg Vol (1m):
7,402,815
Market Cap $:
59.40 Bil
Enterprise Value $:
70.01 Bil
P/E (TTM):
12.80
P/B:
6.12
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Equity-to-Asset | 0.36 | ||
| Debt-to-Equity | 1.12 | ||
| Debt-to-EBITDA | 5.86 | ||
| Interest Coverage | 3.68 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 2.34 | ||
| Beneish M-Score | -2.31 | ||
| WACC vs ROIC | |||
Profitability Rank | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 16.2 | ||
| Net Margin % | 43.78 | ||
| ROE % | 51.79 | ||
| ROA % | 20.22 | ||
| ROC (Joel Greenblatt) % | 31.12 | ||
| 3-Year Revenue Growth Rate | 7.9 | ||
| 3-Year EBITDA Growth Rate | 82.5 |
Valuation Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 12.8 | ||
| Forward PE Ratio | 24.04 | ||
| PE Ratio without NRI | 12.8 | ||
| Price-to-Owner-Earnings | 40.75 | ||
| PB Ratio | 6.12 | ||
| PS Ratio | 5.78 | ||
| Price-to-Free-Cash-Flow | 76.79 | ||
| Price-to-Operating-Cash-Flow | 51.66 | ||
| EV-to-EBIT | 60.41 | ||
| EV-to-EBITDA | 37.66 | ||
| EV-to-Revenue | 6.52 | ||
| PEG Ratio | 1.47 | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 0.77 | ||
| Days Inventory | 149.8 | ||
| Days Sales Outstanding | 61.06 | ||
| Days Payable | 59.97 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 3.97 | ||
| Price-to-Median-PS-Value | 2.38 | ||
| Earnings Yield (Greenblatt) % | 1.66 | ||
| Forward Rate of Return (Yacktman) % | -16.19 |